Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $96.56 Analyst target: $122.33 Upside: 26.69%
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.